Treatment of CML is performed with the tyrosine kinase inhibitor (TKI), imatinib, which acts directly on the BCR-ABL protein by decreasing its intracellular activity and, thus, controlling the carcinogenic environment [5]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.